KD6001
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer[1].
Product Specifications
CAS Number
2983061-18-1
UNSPSC
12352203
Target
CTLA-4
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Janss T, et al. EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance[J]. Cancer Research, 2025, 85 (8_Supplement_1) : 3136-3136.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC550017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF555 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC700745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF770 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
